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Abstract Protein engineering allows the generation of hybrid
polypeptides with functional domains from di¡erent origins and
therefore exhibiting new biological properties. We have explored
several permissive sites in Escherichia coli L-galactosidase to
generate functional hybrid enzymes displaying a mouse scFv
antibody fragment. When this segment was placed at the ami-
no-terminus of the enzyme, the whole fusion protein was stable,
maintained its speci¢c activity and interacted speci¢cally with
the target antigen, a main antigenic determinant of foot-and-
mouth disease virus. In addition, the antigen-targeted enzyme
was enzymatically active when bound to the antigen and there-
fore useful as a reagent in single-step immunoassays. These
results prove the £exibility of E. coli L-galactosidase as a car-
rier for large-sized functional domains with binding properties
and prompt the further exploration of the biotechnological ap-
plicability of the scFv enzyme targeting principle for diagnosis
or other biomedical applications involving antigen tagging.
$ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein engineering allows a modular design of non-natural
polypeptides, in which di¡erent functions associated with in-
dependent domains from di¡erent origins can be combined in
a desirable way to serve speci¢c purposes. Examples of such
multifunctional hybrid proteins include vehicles for delivery of
targeted DNA [1] or functional enzymes [2] and molecular
sensors [3]. The Escherichia coli L-galactosidase is a homote-
trameric enzyme [4] widely employed as a convenient tool in
molecular and cell biology. Its tolerance to both terminal
fusions [5] and inner peptide insertions [6] has prompted its
use as a carrier to stabilize recombinant proteins [7], as a
puri¢cation tag [8] and as a reporter for analysis of gene
expression through gene fusions [9]. The availability of di¡er-
ent substrates rendering colored, £uorescent or luminescent
components enhances the versatility of this enzyme for ¢ne
analytic determinations, simple ELISA tests or in situ deter-
minations of gene expression. In this work, we have explored
several tolerant sites of this enzyme, previously identi¢ed by
insertional mutagenesis and gene fusion [6,10], to display a
functional, single-chain antibody fragment (scFv) keeping
both the enzymatic activity and the antigen binding proper-
ties. The feasibility of this approach would allow the use of
this hybrid enzyme for the tagging of speci¢c antigens and
among other possibilities, its application as a single molecule
reagent in conventional ELISA. The obtained results indicate
that the amino-terminus of this enzyme is capable of accepting
an antiviral scFv antibody and that the hybrid protein is
produced in E. coli at a signi¢cant yield. The antibody^
enzyme chimera speci¢cally recognized the antigen against
which the parental antibody was elicited and it was enzymati-
cally active while bound to the antigen.
2. Materials and methods
2.1. Bacterial strains, plasmids, and cloning strategy
The E. coli K12 strain MC1061 ((F3, V3), v(araA-leu)7697, v(cod-
lacI)3, araD139, galE15, galK16, hsdR2, mcrA, mcrB, relA1, rpsL150
(strR), spoT1) was used for cloning purposes. Fusion proteins were
produced in the protease-de¢cient E. coli strain BL26, a Lac3 deriv-
ative of BL21 (dcm, hsdS, gal, Lon3, OmpT3) [11]. All the recombi-
nant vectors constructed in this work derive from pJLACZ [12], en-
coding a pseudo-wild type E. coli L-galactosidase enzyme whose
production is driven by both V pL and pR promoters placed in tandem
and controlled by the thermolabile cI857 repressor, encoded by the
same vector.
Plasmids pPA278SD6, pPANlacZSD6 and pPAlacZCSD6 were
constructed to present the scFv93 protein inserted between residues
279 and 280 (within the activating interface of the enzyme) or fused to
either the amino- or carboxy-terminus of L-galactosidase respectively
(Fig. 1). scFv93 is a recombinant version of the SD6 antibody, which
binds speci¢cally to a main B-cell epitope from foot-and-mouth dis-
ease virus (FMDV) from serotype C1, sited in the VP1 capsid protein
[13]. The scFv93-encoding DNA was generated by PCR ampli¢cation
(driven by the proofreading Deep Vent0 DNA polymerase) from
plasmid pCASD6 93 [14], using two alternative pairs of complemen-
tary oligonucleotides. The pair CSD6S (5P-GGG ATC CCA GGT
GAA ACT GCA GC-3P) and CSD6R (5P-GGG ATC CCC GTT
TTA TTT CCA GC-3P) was used to obtain a product for ligation
into the EcoRI-digested vector pJLACZ, resulting in vector pPA-
lacZCSD6. The pair NSD6S (5P-GGA TCC CAG GTG AAA CTG
CAG C-3P) and NSD6R (5P-GGG GAT CCC CGT TTT ATT TCC
AGC-3P) was used to obtain a product for ligation into the NcoI-
digested vector pJLACZ, resulting in vector pPANlacZSD6. For clon-
ing at position 279^280, the product of ampli¢cation with the NSD6S-
NSD6R pair was digested with BamHI and repaired with Klenow
enzyme. Then, the DNA segment was ligated into the ClaI-digested
vector pJLACZ, also repaired with Klenow enzyme, resulting in the
vector pPA278SD6.
2.2. Cultures, protein production and enzymatic assays
Plasmid-containing cell cultures were grown at 28‡C and 250 rpm in
200 ml of Luria^Bertani (LB) medium [15] plus 100 Wg/ml ampicillin
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until they reached OD550 0.3, and then were transferred to a water
bath warmed at 42‡C, where recombinant gene expression was al-
lowed for 3 h at 250 rpm. L-Galactosidase activity of bacterial cul-
tures was assayed as described [16] in samples of 0.1 ml plus 0.9 ml of
Z bu¡er (0.06 M Na2HPO4, 0.04 M NaH2PO4, 0.01 M KCl, 1 mM
MgSO4, pH 7) at 28‡C. The reaction was initiated with 200 Wl of
4 mg/ml ortho-nitrophenyl L-D-galactopyranoside (ONPG) in phos-
phate bu¡er [16], and when the yellow color was evident it was
stopped with 500 Wl of 1 M Na2CO3. The absorbance of the samples
was read at 414 nm in a Labsystems iEMS Reader MF.
2.3. SDS^PAGE and Western blotting
Producing bacterial cells were harvested and concentrated (40U) by
low-speed centrifugation and pellets were resuspended in 3 ml of TM
bu¡er (20 mM Tris^HCl, 10 mM MgCl2, pH 7.2) supplemented with
one protease inhibitor cocktail tablet (Roche) per 7 ml of TM bu¡er.
When necessary, soluble and insoluble cell fractions were separated by
centrifugation at 16 000Ug and 4‡C for 10 min, and boiled separately
in Laemmli bu¡er [17], loaded on 7.5% SDS^PAGE and blotted onto
nitrocellulose sheets. Proteins were immunodetected with anti-L-galac-
tosidase rabbit serum (1/500) obtained against the commercial en-
zyme. Anti-rabbit antibodies coupled to horseradish peroxidase were
obtained from Bio-Rad and used at 1/2000. Bands were developed
with H2O2 and 4-chloro-1-naphthol as a substrate. Blot images were
obtained in a Hewlett-Packard high-resolution scanner and relevant
bands were quanti¢ed by using Quantity One software from Bio-Rad.
Speci¢c activity of soluble PANlacZSD6 was calculated from the en-
zymatic activity and the fusion protein amount in cell extracts, 2 h
after induction of gene expression.
2.4. Peptides and ELISA
The 21-mer linear peptide A21 (YTASARGDLAHLTTTHA-
RHLP) reproduces a segment of the G-H loop from FMDV VP1
protein, the antigenic site A, which includes the antibody SD6
B-cell epitope [13]. The 13-mer control peptide P2 (CSGKLICT-
TAVPW) reproduces an immune-relevant B-cell epitope from gp41
of HIV [18]. Binding of PANlacZSD6 to peptides was tested in solid
phase by sandwich ELISA as follows. Di¡erent amounts of peptide
A21 or the control peptide P2 from HIV ranging from 0.08 to 100
pmol were incubated overnight at 4‡C as coating antigens in micro-
titer plates. After washing, wells were blocked overnight at 4‡C with
300 Wl of blocking bu¡er (5% non-fat dry milk in phosphate-bu¡ered
saline containing one protease inhibitor cocktail tablet per 7 ml of
bu¡er). Plates were washed and incubated overnight at 4‡C with 100
Wl of a 1:1 mixture of blocking bu¡er and 40U concentrated soluble
fraction of BL26/PANlacZSD6 cells, obtained 2 h after induction of
gene expression. After washing, rabbit anti-L-galactosidase serum di-
luted 1/1000 was added and after an overnight incubation at 4‡C,
plates were washed and further incubated with a solution of goat
anti-rabbit IgG (H+L) horseradish peroxidase conjugate (Bio-Rad)
under the same conditions. After extensive washing, peroxidase reac-
tion was done by adding a standard solution of H2O2, 3-dimethyla-
minobenzoic acid and 3-methyl-2-benzothiazolinone as substrates
(Sigma). The reaction was stopped with 2 M H2SO4 and the resulting
blue color was read at 620 nm. Monoclonal antibody SD6 at 18.7
ng/Wl and protein LACZ in cell extracts prepared as for PANlacZSD6
were used as positive and negative controls respectively for binding to
peptide A21. SD6 was detected with a goat anti-mouse IgG horse-
radish peroxidase conjugate (Bio-Rad).
For the ELISA revealed through the L-galactosidase activity of
PANlacZSD6, microtiter plates were incubated overnight at 4‡C
with peptide A21 or P2 and washing and blocking steps were per-
formed as described above. The incubation with the recombinant
protein was done overnight at 4‡C. Plates were washed and bound
protein was detected by using 4 mg/ml ONPG in Z bu¡er. The reac-
tion was stopped with 1 M Na2CO3 after 2 h incubation at 28‡C and
the absorbance was read at 414 nm in a Labsystems iEMS Reader
MF. All the ELISA tests were done in triplicate.
3. Results
3.1. Bacterial production of ScFv^L-galactosidase
fusion proteins
After construction and checking, plasmids pPA278SD6,
pPANlacZSD6 and pPAlacZCSD6 were transformed into
E. coli BL26. Recombinant cells were grown in LB medium
without any symptom of toxicity, reaching the same biomass
as the control BL26/pJLACZ cultures (not shown). Three
hours after the temperature shift, the enzymatic activity
was 14 354.2T 1191.1, 9477.1T 813.7 and 5439.6T 124.8 U/ml
forpJLACZ-, pPAlacZCSD6- and pPANlacZSD6-bearing cul-
tures respectively, but it was undetectable in BL26/pPA278-
SD6 cells. These data suggested di¡erential proteolysis of the
fusions, which was con¢rmed by SDS^PAGE and further
Western blot analysis of cell extracts. The full-length form
of pPANlacZSD6 was clearly observed, representing between
25 and 30% of the total anti-L-galactosidase-immunoreactive
protein, being mainly a 90 kDa degradation fragment (Fig. 2).
Traces of a L-galactosidase-like fragment were also visualized.
However, no intact forms of PA278SD6 and PAlacZCSD6
were detected at any post-induction time, these proteins oc-
curring only as degradation fragments (not shown). The en-
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Fig. 1. Schematic representation of the engineered L-galactosidase proteins, indicating the location of the scFv93 insertion in the primary se-
quence of each construct (black boxes). The inserted segment is 247 amino acids in length. The complementarity determining regions are indi-
cated in bold and the linker in italics and underlined. The numbering of the heavy and light chains is according to the sequence of the parental
monoclonal antibody SD6 [13]. The amino acid residues of L-galactosidase, £anking the heterologous stretches, are also indicated by asterisks.
The corresponding numbering is according to Fowler and Zabin [31].
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zymatic activity associated with PAlacZCSD6 production
must then be essentially due to enzymatically active degrada-
tion fragments.
Therefore, only the amino-terminal fusion PANlacZSD6
was further characterized regarding both productivity and
functionality. After cell fractionation, about 90% of PAN-
lacZSD6 was found in the soluble cell fraction while the rest
remained associated with the insoluble cell material. The spe-
ci¢c activity was calculated to be 2223.48T 92.76 U/Wg, similar
to that previously reported (2765T 347 U/Wg) for the parental,
pseudo-wild type L-galactosidase LACZ [6]. Two hours after
induction of gene expression, the productivity in shaker £asks
of the soluble, full-length form of PANlacZSD6 was found to
be 1.1 Wg/ml culture.
3.2. Speci¢c binding and enzymatic activity of PANlacZSD6
To evaluate the proper solvent exposure and binding spec-
i¢city of the scFv domain as displayed on the surface of
PANlacZSD6, a capture ELISA was performed with the
A21 SD6 epitope peptide and the SD6-irrelevant P2 peptide
as bound antigens. As shown in Fig. 3, PANlacZSD6 but not
the parental LACZ protein was retained by A21 (but not by
P2), as determined by an anti-L-galactosidase antibody. This
fact proved the correct presentation and binding speci¢city of
the recombinant fusion version of SD6. To evaluate if in the
bound state PANlacZSD6 was able to retain its enzymatic
activity, an additional capture ELISA was performed in which
the binding of the fusion was monitored by its enzymatic
activity. Fig. 4 shows the increase of L-galactosidase activity
retained by growing amounts of A21, demonstrating that the
fusion protein is active even when interacting with the antigen
through its amino-terminal scFv domain. This result indicates
that scFv^L-galactosidase fusions are appropriate tools for
molecular targeting and con¢rms the plasticity of this enzyme
for diverse biotechnological purposes.
4. Discussion
Being an enormous tetrameric enzyme, the tolerance of
E. coli L-galactosidase to both end-terminal protein fusions
and inner peptide insertions is remarkable [5,6]. In previous
works, we had inserted up to 45-mer peptides in the close
vicinity of the active site, maintaining the enzymatic activity
of the hybrid proteins [6,10,19]. In most of the identi¢ed per-
missive sites the foreign peptide was solvent-exposed, antigen-
ic and available for ligand^receptor interactions with target
molecules [20,21]. However, the proteolytic stability of some
of these constructs was seriously impaired by speci¢c foreign
stretches [19]. On the other hand, an extensive degradation
was also observed in a carboxy-terminal fusion (the equivalent
amino-terminal version being much more stable) carrying a 23
kDa heterologous protein [22]. In this work we tried three
acceptor sites of the enzyme (namely the two terminal ends
and an inner permissive site) for the solvent display of an scFv
to construct an antigen-targeted recombinant enzyme (Fig. 1).
Among them, only the amino-terminus of L-galactosidase tol-
erated the engineered protein domain of 247 amino acids re-
producing the paratope of the monoclonal antibody SD6.
Fig. 2. Western blot analysis of soluble PANlacZSD6 produced in
E. coli BL26, 2 h after induction of gene expression. The upper
band in the right lane corresponds to the full-length PANlacZSD6
(146 kDa). L-Galactosidase markers ranging from 500 ng to 125 ng
were loaded in the left lanes. Lane MW indicates molecular weight
markers whose apparent masses are indicated by arrows.
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Fig. 3. Binding of protein PANlacZSD6 to peptides A21 (black tri-
angles) and P2 (white triangles) as measured by an anti-L-galactosi-
dase monoclonal antibody. The union of the monoclonal antibody
SD6 to A21 (black circles) and P2 (white circles) is also presented.
Note that the absolute absorbance values of PANlacZSD6 and SD6
are not comparable as the second antibody is di¡erent in both
cases. The background binding of LACZ protein to peptide A21
(black squares) and peptide P2 (white squares) is also shown as a
control.
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Fig. 4. Binding of protein PANlacZSD6 to peptides A21 (white
circles) and P2 (black circles) as measured by the PANlacZSD6
L-galactosidase activity.
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Although partial degradation of this protein (named PAN-
lacZSD6) was also detected (Fig. 2), around 30% of the
L-galactosidase-immunoreactive material occurred in its full-
length form. Also, it was mainly produced as a soluble protein
and at reasonably high yields, without signi¢cant reduction of
speci¢c activity when compared with the parental LACZ pro-
tein. Therefore, these results support a high tolerance of the
L-galactosidase amino-terminus versus the sensitivity of the
carboxy-terminus, and prompt the further discarding of posi-
tions 279^280 (being permissive to short peptides), to accom-
modate large protein domains.
On the other hand, protein PANlacZSD6 recognizes specif-
ically the SD6 target antigen (Fig. 3) and maintains its enzy-
matic activity in the bound state (Fig. 4). This is especially
important because the activity of E. coli L-galactosidase can
be a¡ected by the binding of antibodies directed against either
enzyme epitopes [23] or inserted antigenic peptides [19,24]. In
addition, the dual activity of PANlacZSD6 (namely antigen
binding and catalytic properties) can be extremely useful in the
biomedical context for tagging speci¢c antigens. An immedi-
ate example is the application of this principle in diagnostic
immunoassays through the use of single-chain enzymatic anti-
bodies produced in recombinant organisms. However, the
spectrum of possibilities for such an enzyme^antibody fusion
protein could also eventually embrace therapeutic purposes.
End-terminal fusions between alkaline phosphatase and
antibody fragments have been previously reported for antigen
targeting and to circumvent the use of a second, conjugated
antibody in ELISA [25^27]. However, E. coli L-galactosidase
possesses a wider substrate spectrum including ONPG, chlor-
ophenol red-L-D-galactopyranoside, 5-bromo-4-chloro-3-in-
doxyl-L-D-galactopyranoside, Galacton0, £uorescein di-L-
D-galactopyranoside, phenylethyl L-D-thiogalactopyranoside
and L-methylumbelliferyl L-D-galactopyranoside, that render-
ing either colored, £uorescent or luminescent products allows
di¡erent analytical strategies. In addition, the easiness of its
single-step puri¢cation chromatography [28] and the permis-
sivity of this enzyme to multiple peptide insertions [29,30]
would allow not only a fast, sensitive and £exible enzymatic
determination in automated systems but also its further engi-
neering and bioproduction to display additional protein do-
mains for a new combination of desired functions.
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